3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 2
1
Phase 1
1
Status
Withdrawn
1
Recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
4
OTHER
1
Study Type
Interventional
4
Sponsor
Cancer Type
Plasma cell
4
Conditions
Multiple Myeloma
31
Recurrence
4
Renal Insufficiency
1
Kidney Failure, Chronic
1
Immunoglobulin Light-chain Amyloidosis
1
Amyloidosis
1
Interventions
Dexamethasone
64
Cyclophosphamide
35
pomalidomide
34
Lenalidomide
34
Rituximab
31
Bortezomib
30
venetoclax
28
fludarabine
27
Gemcitabine
21
carfilzomib
20
Paclitaxel
19
pembrolizumab
17
daratumumab
17
Cisplatin
16
Carboplatin
15
Calcium Dobesilate
14
Azacitidine
14
ibrutinib
12
Docetaxel
12
Cytarabine
12
obinutuzumab
11
Nivolumab
11
durvalumab
10
Injections
10
Doxorubicin
10
Bevacizumab
10
selinexor
9
cemiplimab
9
blinatumomab
9
Cetuximab
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
INDUSTRY
×
Recurrence
×
belantamab mafodotin
×
Clear all
NCT05714839
2026-05-22
DREAMM-20
GlaxoSmithKline
Phase 1/2
Recruiting
152 enrolled
NCT05064358
2026-05-05
DREAMM 14
GlaxoSmithKline
Phase 2
Completed
177 enrolled
37 charts
NCT02343042
2026-05-04
STOMP
Karyopharm Therapeutics Inc
Phase 1/2
Active not recruiting
300 enrolled
NCT04398680
2025-12-04
DREAMM 13
GlaxoSmithKline
Phase 1
Withdrawn